<DOC>
	<DOCNO>NCT02287662</DOCNO>
	<brief_summary>The primary objective trial provide rigorous assessment efficacy , feasibility safety Vancouver 3M Clinical Pathway protocol patient undergo elective transfemoral TAVR balloon expandable valve .</brief_summary>
	<brief_title>The Multidisciplinary , Multimodality , But Minimalist Approach Transfemoral Transcatheter Aortic Valve Replacement</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Patients severe symptomatic aortic stenosis undergo elective transfemoral TAVR balloon expandable transcatheter heart valve 1 . Considered increase surgical risk Multidisciplinary Heart Team . 2 . Informed write consent 1 . Non cardiovascular comorbidity reduce life expectancy &lt; 3 year 2 . Any factor preclude 1 year followup 3 . Inadequate CT image acquisition perform areabased annular CT sizing , exclude adverse root feature , determine coaxial valve deployment angle ( CT require valveinvalve procedure ) 4 . Predicted inability perform uncomplicated percutaneous vascular access closure 5 . Iliofemoral diameter &lt; 6 mm SAPIEN XT &lt; 5.5 mm SAPIEN 3 ( measure midfemoral head ) 6 . Inpatient ( unless clinically stable , mobilize baseline , primarily hospital logistical reason . 7 . Significant communication barrier ( ) interfere ability follow periprocedural discharge instruction 8 . MMSE &lt; 24/30 ( unless language barrier limit formal education ) , 5metre gait &gt; 7 second ( unless chronic mobility impairment affect ability perform ADLs ) , ADL &lt; 6/6 9 . Insufficient social support facilitate next day discharge 10 . Airway unfavourable emergent intubation 11 . Inability lay supine without conscious sedation general anesthetic 12 . Not receive balloon expandable transcathter heart valve</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
</DOC>